Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of Biochemical and Molecular Toxicology

Ameliorative Effect of Lycopene and Capsaicinoid Glucoside in Acute Myeloid Leukemia

  • Somia Shehzadi1
  • Muhammad Abbas Shahid2
  • Shaista Nazir3
  • Murtaza Mansoor4
  • Asmat Ullah5
  • Fatima Iftikhar Shah1
  • Zaid Talal Abdulqader Ali6
6 affiliations
  1. 1University Institute of Medical Laboratory Technology The University of Lahore Lahore Pakistan
  2. 2Glenfield Hospital Leicester UK
  3. 3Institute of Blood Transfusion Services Lahore Pakistan
  4. 4Punjab Institute of Cardiology Lahore Pakistan
  5. 5College of Pharmaceutical Sciences Zhejiang University of Technology Hangzhou China
  6. 6Faculty of Medicine University of Saba Region Marib Yemen
Read full textPDFDOICite

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy with limited therapeutic efficacy, particularly in elderly and chemotherapy‐resistant patients. Although cytarabine and daunorubicin are the conventional treatments, their 5‐year survival rate is less than 15% in some populations. Nonetheless, natural bioactive substances with antileukemic properties might be a viable treatment strategy. The antileukemic potential of lycopene (Lyc) and capsaicinoid glucoside (CG), individually and in combination, is examined in this study as a possible adjuvant or alternative treatment. This study employed both in‐vitro (HL‐60 cell line) and in‐vivo (benzene‐induced leukemia rat model) methods. Cytotoxicity, apoptosis, and proliferation were evaluated in‐vitro using MTT assays, Trypan blue, crystal violet staining and flow cytometry (Annexin‐V/PI). Hematological parameters (WBC, RBC, neutrophils), oxidative stress indicators (SOD, GSH), qPCR and ELISA for anti‐apoptotic/proliferative markers (Bcl‐2, NF‐κB, Ki‐67, PCNA) were assessed in in vivo tests. To verify morphological alterations, blood smear analysis was carried out. Lyc and CG showed dose‐dependent cytotoxicity in vitro, synergistically Lyc+CG showed lowest cytotoxicity with IC50 values of 21.35. Synergistic effects were shown by the Lyc+CG combination, which dramatically decreased cell viability and increased apoptosis (40.59% early apoptosis, 18.72% late apoptosis). In‐vitro and in‐vivo study showed that Lyc+CG reduced proliferation and anti‐apoptotic effect, restored SOD and GSH levels, and normalized haematological parameters (p < 0.001). The Lyc+CG group's blood smears revealed more apoptotic bodies and fewer blast cells. By causing apoptosis, lowering oxidative stress, and preventing proliferation in cell line (HL‐60) and animal models (benzene‐induced leukemia in rats), the combination of Lyc and CG demonstrates strong antileukemic action. These results encourage more research into Lyc+CG as a possible AML treatment approach. To completely clarify its therapeutic potential, future research should concentrate on clinical trials and molecular insights.

Related

  1. A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report
    Mostafa Kamandi, Mohammad Mahdi Alvandi Fard
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review
    Emmanuel Ifeanyi Obeagu
    Health science reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Clinical features, epidemiology, and survival of patients with core binding factor acute myeloid leukemia in the SEER database
    Shan Liu, Yaobin Lin, Jianzhen Shen
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review
    Joseph Han, Farid Ghamsari, Jessica Yan +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
    Xiaoyue Ren, Lijie Zhang, Linli Zhou +1
    ImmunotherapyPeer-reviewedLicence not statedFull textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{shehzadi2026ameliorative,
  title = {{Ameliorative Effect of Lycopene and Capsaicinoid Glucoside in Acute Myeloid Leukemia}},
  author = {Somia Shehzadi and Muhammad Abbas Shahid and Shaista Nazir and Murtaza Mansoor and Asmat Ullah and Fatima Iftikhar Shah and Zaid Talal Abdulqader Ali},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  month = oct,
  doi = {10.1002/jbt.71162},
  url = {https://doi.org/10.1002/jbt.71162},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Ameliorative Effect of Lycopene and Capsaicinoid Glucoside in Acute Myeloid Leukemia
AU  - Somia Shehzadi
AU  - Muhammad Abbas Shahid
AU  - Shaista Nazir
AU  - Murtaza Mansoor
AU  - Asmat Ullah
AU  - Fatima Iftikhar Shah
AU  - Zaid Talal Abdulqader Ali
PY  - 2026
DA  - 2026/10/27
JO  - Journal of Biochemical and Molecular Toxicology
DO  - 10.1002/jbt.71162
UR  - https://doi.org/10.1002/jbt.71162
AB  - Acute myeloid leukemia (AML) is a hematological malignancy with limited therapeutic efficacy, particularly in elderly and chemotherapy‐resistant patients. Although cytarabine and daunorubicin are the conventional treatments, their 5‐year survival rate is less than 15% in some populations. Nonetheless, natural bioactive substances with antileukemic properties might be a viable treatment strategy. The antileukemic potential of lycopene (Lyc) and capsaicinoid glucoside (CG), individually and in combination, is examined in this study as a possible adjuvant or alternative treatment. This study employed both in‐vitro (HL‐60 cell line) and in‐vivo (benzene‐induced leukemia rat model) methods. Cytotoxicity, apoptosis, and proliferation were evaluated in‐vitro using MTT assays, Trypan blue, crystal violet staining and flow cytometry (Annexin‐V/PI). Hematological parameters (WBC, RBC, neutrophils), oxidative stress indicators (SOD, GSH), qPCR and ELISA for anti‐apoptotic/proliferative markers (Bcl‐2, NF‐κB, Ki‐67, PCNA) were assessed in in vivo tests. To verify morphological alterations, blood smear analysis was carried out. Lyc and CG showed dose‐dependent cytotoxicity in vitro, synergistically Lyc+CG showed lowest cytotoxicity with IC50 values of 21.35. Synergistic effects were shown by the Lyc+CG combination, which dramatically decreased cell viability and increased apoptosis (40.59% early apoptosis, 18.72% late apoptosis). In‐vitro and in‐vivo study showed that Lyc+CG reduced proliferation and anti‐apoptotic effect, restored SOD and GSH levels, and normalized haematological parameters (p < 0.001). The Lyc+CG group's blood smears revealed more apoptotic bodies and fewer blast cells. By causing apoptosis, lowering oxidative stress, and preventing proliferation in cell line (HL‐60) and animal models (benzene‐induced leukemia in rats), the combination of Lyc and CG demonstrates strong antileukemic action. These results encourage more research into Lyc+CG as a possible AML treatment approach. To completely clarify its therapeutic potential, future research should concentrate on clinical trials and molecular insights.
SN  - 1095-6670
SN  - 1099-0461
ER  -